Skip to main content

Booth Bruce's Form 4 filing

Kymera Therapeutics, Inc. (KYMR) · filed Jun 14, 2024

Accession no.
0001415889-24-017005
Filed
Jun 14, 2024
Trade date
Jun 12-13, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions. Open-market sales total $950.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Booth BruceCIK 0001451612Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 12, 2024Common StockSSaleDisposed−11,838$35.35F2−$418,473.34,558,827Indirect
Jun 12, 2024Common StockSSaleDisposed−1,997$36.02F4−$71,931.944,556,830Indirect
Jun 12, 2024Common StockSSaleDisposed−2,485$35.35F2−$87,844.75804,212Indirect
Jun 12, 2024Common StockSSaleDisposed−420$36.02F4−$15,128.4803,792Indirect
Jun 13, 2024Common StockSSaleDisposed−8,430$34.98F7−$294,881.44,548,400Indirect
Jun 13, 2024Common StockSSaleDisposed−1,770$34.98F7−$61,914.6802,022Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $35.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7).

Referenced by the price of 2 transactions in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.29 inclusive.

Referenced by the price of 2 transactions in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $34.985 inclusive.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)